India, Oct. 12 -- Ardelyx, Inc. (ARDX), a commercial-stage biopharmaceutical company, announced real-world data showing reduced gastrointestinal-related healthcare resource utilization among adults with irritable bowel syndrome with constipation (IBS-C) following initiation of IBSRELA (tenapanor). The findings are being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting.
Irritable bowel syndrome with constipation (IBS-C) is a gastrointestinal disorder characterized by abdominal pain, bloating, and difficult or infrequent bowel movements. The condition can significantly affect daily activities and quality of life.
IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (N...